ERS Genomics Licenses CRISPR/Cas9 to Knudra Transgenics

Nov 02, 2016 | staff reporter

NEW YORK (GenomeWeb) – ERS Genomics announced today that it has agreed to license CRISPR/Cas9 genome editing to Knudra Transgenics, a firm that engineers model organisms for biological research.

Under the terms of the worldwide license, Salt Lake City-based Knudra has obtained the rights to edit the genomes of the roundworm *Caenorhabditis elegans* and the zebrafish *Danio rerio*. Financial and other terms of the agreement were not disclosed.

"Knudra is a great example of how a smaller company, dedicated to building platforms for medical discovery, can benefit from use of this exciting new technology," ERS CEO Eric Rhodes said in a statement.

Emmanuelle Charpentier of the Max Planck Institute for Infection Biology co-founded the privately-held, Dublin-based ERS Genomics in 2014 to commercialize patent rights she holds as an inventor on a CRISPR patent application. The firm recently licensed CRISPR/Cas9 technology to Evolva for industrial applications.

Filed Under Gene Silencing/Gene Editing Business News Drug Discovery & Development licensing agreement CRISPR gene editing

Privacy Policy. Copyright © 2016 GenomeWeb LLC. All Rights Reserved.